Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16988659 | 0.79 | ESR1 (0.42) | SLC6A4SLC6A3ESR1ESR2 | |
| SCHEMBL4232429 | 0.79 | ESR1 (0.42) | SLC6A4SLC6A3ESR1ESR2 | |
| SCHEMBL13918280 | 0.77 | SLC15A1 (0.38) | ACE | |
| SCHEMBL13910069 | 0.70 | ALDH1A1 (0.34) | CAPN1ACECTSB | |
| SCHEMBL16988319 | 0.66 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL16988571 | 0.66 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL4237639 | 0.64 | ESR1 (0.33) | ESR1ESR2LMNA | |
| SCHEMBL4237636 | 0.64 | ESR1 (0.33) | ESR1ESR2LMNA | |
| SCHEMBL4227584 | 0.63 | CYP1A2 (0.37) | LMNA | |
| SCHEMBL4227589 | 0.63 | CYP1A2 (0.37) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | UNIVERSITAT DORTMUND (DE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | CHAT, DLAT, CPT1A | CAPN1 3069/4885SLC6A4 678/4885SLC6A3 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.